Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2019 | May 10, 2019 | |
Document Information [Line Items] | ||
Entity Registrant Name | WINDTREE THERAPEUTICS INC /DE/ | |
Entity Central Index Key | 0000946486 | |
Trading Symbol | wint | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Common Stock, Shares Outstanding (in shares) | 32,188,855 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Current Assets: | ||
Cash and cash equivalents | $ 2,053 | $ 11,187 |
Available-for-sale marketable securities | 13,514 | 13,959 |
Prepaid expenses and other current assets | 502 | 507 |
Total current assets | 16,069 | 25,653 |
Property and equipment, net | 826 | 802 |
Restricted cash | 171 | 171 |
Operating lease right-of-use assets | 1,788 | |
Indefinite intangible asset | 77,090 | 77,090 |
Goodwill | 15,682 | 15,682 |
Total assets | 111,626 | 119,398 |
Current Liabilities: | ||
Accounts payable | 1,417 | 3,420 |
Collaboration and device development payable, net | 1,939 | 2,576 |
Accrued Liabilities, Current, Total | 5,247 | 6,465 |
Operating lease liabilities - current portion | 730 | |
Deferred revenue | 158 | 198 |
Loan payable | 7,469 | 7,974 |
Total current liabilities | 16,960 | 20,633 |
Operating lease liabilities - non-current portion | 1,251 | |
Restructured debt liability - contingent milestone payments | 15,000 | 15,000 |
Deferred tax liabilities | 15,356 | 15,476 |
Other liabilities | 63 | 175 |
Total liabilities | 48,630 | 51,284 |
Stockholders' Equity: | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2019 and December 31, 2018 | 0 | 0 |
Common stock, $0.001 par value; 120,000,000 shares authorized at March 31, 2019 and December 31, 2018; 32,188,929 and 32,133,263 shares issued at March 31, 2019 and December 31, 2018, respectively; 32,188,855 and 32,133,189 shares outstanding at March 31, 2019 and December 31, 2018, respectively | 32 | 32 |
Additional paid-in capital | 730,162 | 728,783 |
Accumulated deficit | (664,184) | (657,647) |
Accumulated other comprehensive income | 40 | 0 |
Treasury stock (at cost); 74 shares | (3,054) | (3,054) |
Total stockholders' equity | 62,996 | 68,114 |
Total liabilities & stockholders' equity | $ 111,626 | $ 119,398 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Mar. 31, 2019 | Dec. 31, 2018 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 120,000,000 | 120,000,000 |
Common stock, shares issued (in shares) | 32,188,929 | 32,133,263 |
Common stock, shares outstanding (in shares) | 32,188,855 | 32,133,189 |
Treasury stock, shares (in shares) | 74 | 74 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Revenues: | ||
Total revenues | $ 40 | $ 204 |
Expenses: | ||
Research and development | 3,342 | 3,118 |
General and administrative | 3,355 | 1,926 |
Total operating expenses | 6,697 | 5,044 |
Operating loss | (6,657) | (4,840) |
Other income / (expense): | ||
Interest income | 60 | 4 |
Interest expense | (136) | (90) |
Other income | 196 | 414 |
Other income / (expense), net | 120 | 328 |
Net loss | $ (6,537) | $ (4,512) |
Net loss per common share | ||
Basic and diluted (in dollars per share) | $ (0.20) | $ (1.40) |
Weighted average number of common shares outstanding | ||
Basic and diluted (in shares) | 32,142 | 3,227 |
License [Member] | ||
Revenues: | ||
License revenue with affiliate | $ 40 | $ 204 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Net loss | $ (6,537) | $ (4,512) |
Other comprehensive income: | ||
Unrealized gain on marketable securities | 40 | |
Comprehensive loss | $ (6,497) | $ (4,512) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Treasury Stock [Member] | Total |
Balance (in shares) at Dec. 31, 2017 | 3 | 3,227 | |||||
Balance at Dec. 31, 2017 | $ 3 | $ 616,245 | $ (637,114) | $ (3,054) | $ (23,920) | ||
Net loss | (4,512) | (4,512) | |||||
Share Purchase Agreement, April 2018 | (52) | (52) | |||||
Stock-based compensation expense | 418 | 418 | |||||
Unrealized gain on marketable securities | |||||||
Balance (in shares) at Mar. 31, 2018 | 3 | 3,227 | |||||
Balance at Mar. 31, 2018 | $ 3 | 616,611 | (641,626) | $ (3,054) | (28,066) | ||
Balance (in shares) at Dec. 31, 2018 | 32,133 | ||||||
Balance at Dec. 31, 2018 | $ 32 | 728,783 | (657,647) | $ (3,054) | 68,114 | ||
Net loss | (6,537) | (6,537) | |||||
Stock-based compensation expense | 1,530 | 1,530 | |||||
Vesting of restricted stock units (in shares) | 56 | ||||||
Vesting of restricted stock units | |||||||
Withholding tax payments related to net share settlements of restricted stock units (in shares) | |||||||
Withholding tax payments related to net share settlements of restricted stock units | (151) | (151) | |||||
Unrealized gain on marketable securities | 40 | 40 | |||||
Balance (in shares) at Mar. 31, 2019 | 32,189 | ||||||
Balance at Mar. 31, 2019 | $ 32 | $ 730,162 | $ (664,184) | $ 40 | $ (3,054) | $ 62,996 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Cash flows from operating activities: | ||
Net loss | $ (6,537) | $ (4,512) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Recognition of deferred revenue | (40) | (204) |
Depreciation | 50 | 41 |
Amortization of operating lease right-of-use assets | 192 | |
Amortization of debt discount | 55 | |
Stock-based compensation | 1,530 | 418 |
Realized gain on investments | (11) | |
Changes in: | ||
Prepaid expenses and other current assets | 5 | 293 |
Accounts payable | (2,003) | 1,635 |
Collaboration and device development payable | (692) | 49 |
Accrued expenses | (1,118) | (266) |
Operating lease liabilities | (214) | |
Other liabilities | 24 | |
Net cash used in operating activities | (8,759) | (2,546) |
Cash flows from investing activities: | ||
Purchase of property and equipment | (74) | |
Proceeds from sale of marketable securities | 499 | |
Net cash provided by investing activities | 425 | |
Cash flows from financing activities: | ||
Proceeds from loan payable, net of expenses | 2,500 | |
Principle payments on loan payable | (447) | |
Payment for taxes related to net share settlements of restricted stock units | (151) | |
Net cash (used in) / provided by financing activities | (598) | 2,500 |
Effect of exchange rate changes on cash and cash equivalents | (202) | |
Net decrease in cash and cash equivalents | (9,134) | (46) |
Cash, cash equivalents and restricted cash - beginning of year | 11,358 | 2,040 |
Cash, cash equivalents and restricted cash - end of year | $ 2,224 | $ 1,994 |
Note 1 - The Company and Descri
Note 1 - The Company and Description of Business | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1 The Company and Description of Business Windtree Therapeutics, Inc. (referred to as “we,” “us,” or the “Company”) is a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute pulmonary and cardiovascular diseases. Historically, our focus has been on the development of our proprietary KL4 December 21, 2018, $0.001 0.3512 16,265,060 December 21, 2018, may Our four 1 2 KL4 3 KL4 4 The reader is referred to, and encouraged to read in its entirety, Item 1 10 December 31, 2018 April 16, 2019, 10 April 23, 2019 ( 2018 10 |
Note 2 - Basis of Presentation
Note 2 - Basis of Presentation | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Basis of Accounting [Text Block] | Note 2 Basis of Presentation These interim unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the US (US GAAP) for interim financial information in accordance with the instructions to Form 10 not three March 31, 2019 not may December 31, 2019. no December 31, 2018. December 31, 2018 2018 10 |
Note 3 - Liquidity Risks and Ma
Note 3 - Liquidity Risks and Management's Plans | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Liquidity Disclosures [Text Block] | Note 3 – Liquidity Risks and Management’s Plans As of March 31, 2019, $2.1 $13.5 $17.0 $7.5 see 7 May 10, 2019, October 2019. Although we believe that the CVie Acquisition and a $39 may October 2019, not one To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans to raise additional capital through a combination of public or private equity offerings and strategic transactions, including but not none no none not one The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not As of March 31, 2019, 120 5 72.0 5.0 not |
Note 4 - Summary of Significant
Note 4 - Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 4 Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments, CVie Therapeutics, and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.). Business Combinations We follow the acquisition method for an acquisition of a business where the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimate of fair value is based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and as such, actual results may Goodwill and Intangible Assets We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development (IPR&D) assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not may March 31, 2019: (in thousands) Estimated Fair Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090 Goodwill represents the excess of the purchase price over the fair value assets acquired and liabilities assumed in a business combination and is not may not not Foreign Currency Transactions The functional currency for our foreign subsidiaries is US dollars. We remeasure monetary assets and liabilities that are not $0.2 three March 31, 2019. no three March 31, 2018. Use of Estimates The preparation of financial statements, in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Marketable Securities Marketable securities consist of investments in US Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. We classify investments as available-for-sale pursuant to Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) 320, three March 31, 2019, $11,000 $40,000 no three March 31, 2018. We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not Available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security. Leases Effective January 1, 2019, 842, 842 not 840, At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease based on the unique facts and circumstances present in the arrangement. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one not 12 not Operating lease liabilities and their corresponding operating lease right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may not 842, Restructured Debt Liability – Contingent Milestone Payment In conjunction with the November 2017 ee, 8 $15 October 27, 2017 ( not Research and Development We account for research and development expense by the following categories: (a) product development and manufacturing, (b) clinical medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with ASC Topic 730, Net Loss per Common Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of March 31, 2019 2018, 15.2 1.0 three March 31, 2019 2018, Income Taxes We account for income taxes in accordance with ASC Topic 740, We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is not Recently Adopted Accounting Standards In February 2016, No. 2016 02, 2016 02 2016 02 842 840, 842 2018. January 1, 2019 not not January 1, 2019. 840 ASC 842 not 12 not The adoption of this standard resulted in the recognition of operating lease liabilities and related right-of-use assets on our condensed consolidated balance sheets of $2.2 $2.0 842 $72,000 $139,000 not 10 In January 2017, No. 2017 04, 350 second December 15, 2019 January 1, 2019 December 31, 2019. Recently Issued Accounting Standards In August 2018, No. 2018 13, 820 2018 13 820. no 1 2 3 3 3 2018 13 December 15, 2019. 2018 13 |
Note 5 - License Revenue with A
Note 5 - License Revenue with Affiliate | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | Note 5 – License R evenue with A ffiliate Three Months Ended (in thousands) 2019 2018 License revenue with affiliate $ 40 $ 204 License revenue with affiliate for the three March 31, 2019 606. |
Note 6 - Fair Value of Financia
Note 6 - Fair Value of Financial Instruments | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | Note 6 – Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three first two ● Level 1 ● Level 2 1 not ● Level 3 no Fair Value on a Recurring Basis The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented: Fair Value Fair value measurement using March 31, (in thousands) 2018 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 2,053 $ 2,053 $ - $ - U.S. Treasury notes 13,514 13,514 - - Certificate of deposit 171 171 - - Total Assets $ 15,738 $ 15,738 $ - $ - Fair Value Fair value measurement using December 31, (in thousands) 2018 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 5,234 $ 5,234 $ - $ - U.S. Treasury notes 19,912 19,912 - - Certificate of deposit 171 171 - - Total Assets $ 25,317 $ 25,317 $ - $ - |
Note 7 - Loan Payable
Note 7 - Loan Payable | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Short-term Debt [Text Block] | Note 7 – Loan Payable In January 2018 March 2018, $1.5 $1.0 one 6% December 31, 2018. March 1, 2018 ( December 5, 2018, $6.0 $1.5 $1.0 Assumption of bank debt as part of the CVie Acquisition As part of the CVie Acquisition, we assumed approximately $4.5 March 2020. In September 2016, 12 $2.9 $5.8 September 2017. 110% not 90 0.91%. September 11, 2019 six March 11, 2020. not $4.5 As of March 31, 2019, $4.5 Assumption of Lee’s debt as part of the CVie Acquisition As part of the CVie Acquisition, we assumed approximately $3.5 From April 24, 2018 November 16, 2018, four $3.5 4% four one $0.5 April 2019; $0.3 September 2019; $0.2 October 2019; $2.5 November 2019. During the quarter ended March 31, 2019, $0.45 April 2018 $50,000 April 2019. March 31, 2019, $3.0 |
Note 8 - Restructured Debt Liab
Note 8 - Restructured Debt Liability | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Long-term Debt [Text Block] | Note 8 – Restructured D ebt L iability March 31, December 31, (in thousands) 2019 2018 Restructured debt liability - contingent milestone payments $ 15,000 $ 15,000 On November 1, 2017, $25 25,000 $786.80 $2.5 71,111 2% $15 $15 see 4 not |
Note 9 - Stock Options and Stoc
Note 9 - Stock Options and Stock-based Employee Compensation | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | Note 9 – Stock Options and Stock-Based Employee Compensation We recognize in our condensed consolidated financial statements all stock-based awards to employees and non-employee directors based on their fair value on the date of grant, calculated using the Black-Scholes option-pricing model. Compensation expense related to stock-based awards is recognized ratably over the vesting period, which for employees is typically three six 18 A summary of activity under our long-term incentive plan is presented below: Weighted- Weighted- (in thousands, except for weighted-average data) Average Remaining Stock Options Shares Exercise Contractual Outstanding at January 1, 2019 4,417 $ 6.73 Granted 824 4.11 Forfeited or expired (4 ) 576.33 Outstanding at March 31, 2019 5,237 $ 5.91 9.7 Vested and exercisable at March 31, 2019 69 $ 130.39 6.7 Vested and expected to vest at March 31, 2019 4,942 $ 5.89 9.7 (in thousands, except for weighted-average data) Restricted Stock Units Shares Weighted- Unvested at January 1, 2019 151 $ 4.29 Awarded 249 3.95 Vested (95 ) 3.95 Cancelled (144 ) 4.33 Unvested at March 31, 2019 161 $ 4.22 The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following weighted average assumptions: Three Months Ended 2019 Weighted average expected volatility 96 % Weighted average expected term (in years) 6.5 Weighted average risk-free interest rate 2.60 % Expected dividends - The table below summarizes the total stock-based compensation expense included in the statements of operations for the periods presented: Three Months Ended (in thousands) 2019 2018 Research and development $ 489 $ 110 General and administrative 1,041 308 Total $ 1,530 $ 418 |
Note 10 - Leases
Note 10 - Leases | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | Note 1 0 – Leases Our operating leases consist primarily of facility leases for our operations in Warrington, Pennsylvania and Taipei, Taiwan. We maintain our corporate headquarters and operations in Warrington, Pennsylvania, with a remaining non-cancelable term of approximately three Throughout the term of our leases, we are responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. The following table contains a summary of the lease costs recognized under ASC 842 three March 31, 2019: Three Months Ended (in thousands) 2019 Operating lease cost $ 238 Variable lease cost 7 Total lease cost $ 245 Other Information Operating cash flows used for operating leases $ 253 Weighted average remaining lease term (in years) 2.9 Weighted average incremental borrowing rate 9.00 % Future minimum lease payments under our non-cancelable operating leases as of March 31, 2019, Three Months Ended (in thousands) 2019 2019 (excluding the three months ended March 31, 2019) $ 699 2020 666 2021 654 2022 194 2023 28 Thereafter - Total lease payments 2,241 Less imputed interest (260 ) Total operating lease liabilities at March 31, 2019 1,981 The total aggregate base rental payments remaining under the leases as of December 31, 2018 $2.1 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments, CVie Therapeutics, and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.). |
Business Combinations Policy [Policy Text Block] | Business Combinations We follow the acquisition method for an acquisition of a business where the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimate of fair value is based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and as such, actual results may |
Goodwill and Intangible Assets, Policy [Policy Text Block] | Goodwill and Intangible Assets We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development (IPR&D) assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not may March 31, 2019: (in thousands) Estimated Fair Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090 Goodwill represents the excess of the purchase price over the fair value assets acquired and liabilities assumed in a business combination and is not may not not |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign Currency Transactions The functional currency for our foreign subsidiaries is US dollars. We remeasure monetary assets and liabilities that are not $0.2 three March 31, 2019. no three March 31, 2018. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements, in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Marketable Securities, Policy [Policy Text Block] | Marketable Securities Marketable securities consist of investments in US Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. We classify investments as available-for-sale pursuant to Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) 320, three March 31, 2019, $11,000 $40,000 no three March 31, 2018. We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not Available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security. |
Lessee, Leases [Policy Text Block] | Leases Effective January 1, 2019, 842, 842 not 840, At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease based on the unique facts and circumstances present in the arrangement. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one not 12 not Operating lease liabilities and their corresponding operating lease right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may not 842, |
Restructured Debt Liability, Contingent Milestone Payment, Policy [Policy Text Block] | Restructured Debt Liability – Contingent Milestone Payment In conjunction with the November 2017 ee, 8 $15 October 27, 2017 ( not |
Research and Development Expense, Policy [Policy Text Block] | Research and Development We account for research and development expense by the following categories: (a) product development and manufacturing, (b) clinical medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with ASC Topic 730, |
Earnings Per Share, Policy [Policy Text Block] | Net Loss per Common Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of March 31, 2019 2018, 15.2 1.0 three March 31, 2019 2018, |
Income Tax, Policy [Policy Text Block] | Income Taxes We account for income taxes in accordance with ASC Topic 740, We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Standards In February 2016, No. 2016 02, 2016 02 2016 02 842 840, 842 2018. January 1, 2019 not not January 1, 2019. 840 ASC 842 not 12 not The adoption of this standard resulted in the recognition of operating lease liabilities and related right-of-use assets on our condensed consolidated balance sheets of $2.2 $2.0 842 $72,000 $139,000 not 10 In January 2017, No. 2017 04, 350 second December 15, 2019 January 1, 2019 December 31, 2019. Recently Issued Accounting Standards In August 2018, No. 2018 13, 820 2018 13 820. no 1 2 3 3 3 2018 13 December 15, 2019. 2018 13 |
Note 4 - Summary of Significa_2
Note 4 - Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Indefinite-Lived Intangible Assets [Table Text Block] | (in thousands) Estimated Fair Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090 |
Note 5 - License Revenue with_2
Note 5 - License Revenue with Affiliate (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Disaggregation of Revenue [Table Text Block] | Three Months Ended (in thousands) 2019 2018 License revenue with affiliate $ 40 $ 204 |
Note 6 - Fair Value of Financ_2
Note 6 - Fair Value of Financial Instruments (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | Fair Value Fair value measurement using March 31, (in thousands) 2018 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 2,053 $ 2,053 $ - $ - U.S. Treasury notes 13,514 13,514 - - Certificate of deposit 171 171 - - Total Assets $ 15,738 $ 15,738 $ - $ - Fair Value Fair value measurement using December 31, (in thousands) 2018 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 5,234 $ 5,234 $ - $ - U.S. Treasury notes 19,912 19,912 - - Certificate of deposit 171 171 - - Total Assets $ 25,317 $ 25,317 $ - $ - |
Note 8 - Restructured Debt Li_2
Note 8 - Restructured Debt Liability (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Long-term Debt Instruments [Table Text Block] | March 31, December 31, (in thousands) 2019 2018 Restructured debt liability - contingent milestone payments $ 15,000 $ 15,000 |
Note 9 - Stock Options and St_2
Note 9 - Stock Options and Stock-based Employee Compensation (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] | Weighted- Weighted- (in thousands, except for weighted-average data) Average Remaining Stock Options Shares Exercise Contractual Outstanding at January 1, 2019 4,417 $ 6.73 Granted 824 4.11 Forfeited or expired (4 ) 576.33 Outstanding at March 31, 2019 5,237 $ 5.91 9.7 Vested and exercisable at March 31, 2019 69 $ 130.39 6.7 Vested and expected to vest at March 31, 2019 4,942 $ 5.89 9.7 |
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] | (in thousands, except for weighted-average data) Restricted Stock Units Shares Weighted- Unvested at January 1, 2019 151 $ 4.29 Awarded 249 3.95 Vested (95 ) 3.95 Cancelled (144 ) 4.33 Unvested at March 31, 2019 161 $ 4.22 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Three Months Ended 2019 Weighted average expected volatility 96 % Weighted average expected term (in years) 6.5 Weighted average risk-free interest rate 2.60 % Expected dividends - |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended (in thousands) 2019 2018 Research and development $ 489 $ 110 General and administrative 1,041 308 Total $ 1,530 $ 418 |
Note 10 - Leases (Tables)
Note 10 - Leases (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Lease, Cost [Table Text Block] | Three Months Ended (in thousands) 2019 Operating lease cost $ 238 Variable lease cost 7 Total lease cost $ 245 Other Information Operating cash flows used for operating leases $ 253 Weighted average remaining lease term (in years) 2.9 Weighted average incremental borrowing rate 9.00 % |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Three Months Ended (in thousands) 2019 2019 (excluding the three months ended March 31, 2019) $ 699 2020 666 2021 654 2022 194 2023 28 Thereafter - Total lease payments 2,241 Less imputed interest (260 ) Total operating lease liabilities at March 31, 2019 1,981 |
Note 1 - The Company and Desc_2
Note 1 - The Company and Description of Business (Details Textual) | Dec. 21, 2018$ / sharesshares | Mar. 31, 2019$ / shares | Dec. 31, 2018$ / shares |
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 |
CVie Investment [Member] | |||
Business Acquisition, Share Exchange Ratio | 0.3512 | ||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares | 16,265,060 |
Note 3 - Liquidity Risks and _2
Note 3 - Liquidity Risks and Management's Plans (Details Textual) - USD ($) $ in Thousands | Dec. 21, 2018 | Mar. 31, 2019 | Dec. 31, 2018 |
Cash and Cash Equivalents, at Carrying Value, Ending Balance | $ 2,053 | $ 11,187 | |
Debt Securities, Available-for-sale, Current, Total | 13,514 | 13,959 | |
Liabilities, Current, Total | 16,960 | $ 20,633 | |
Loans Payable, Current, Total | $ 7,500 | ||
Private Placement Financing, Value | $ 39,000 | ||
Common Stock, Shares Authorized | 120,000,000 | 120,000,000 | |
Preferred Stock, Shares Authorized | 5,000,000 | 5,000,000 | |
Common Stock, Capital Shares Available for Issuance | 72,000,000 | ||
Preferred Stock, Capital Shares Available for Issuance | 5,000,000 |
Note 4 - Summary of Significa_3
Note 4 - Summary of Significant Accounting Policies (Details Textual) - USD ($) shares in Millions | 3 Months Ended | ||||
Mar. 31, 2019 | Mar. 31, 2018 | Jan. 01, 2019 | Dec. 31, 2018 | Nov. 01, 2017 | |
Foreign Currency Transaction Gain (Loss), before Tax, Total | $ 200,000 | $ 0 | |||
Marketable Securities, Realized Gain (Loss), Total | 11,000 | 0 | |||
Marketable Securities, Unrealized Gain (Loss), Total | 40,000 | $ 0 | |||
Liability for Contingent Milestone Payment, Noncurrent | $ 15,000,000 | $ 15,000,000 | |||
Number of Shares of Common Stock Potentially Issuable upon the Exercise of Stock Options and Warrants | 15.2 | 1 | |||
Operating Lease, Right-of-Use Asset | $ 1,788,000 | ||||
Operating Lease, Liability, Total | 1,981,000 | ||||
Accrued Liabilities, Current, Total | 5,247,000 | 6,465,000 | |||
Other Liabilities, Noncurrent, Total | 63,000 | 175,000 | |||
Accounting Standards Update 2016-02 [Member] | |||||
Operating Lease, Right-of-Use Asset | $ 2,200,000 | ||||
Operating Lease, Liability, Total | 2,000,000 | ||||
Accrued Liabilities, Current, Total | (72,000) | ||||
Other Liabilities, Noncurrent, Total | $ (139,000) | ||||
Deerfield Loan [Member] | |||||
Liability for Contingent Milestone Payment, Noncurrent | $ 15,000,000 | $ 15,000,000 | |||
Deerfield Loan [Member] | Exchange and Termination Agreement [Member] | Deerfield Management, L.P. [Member] | |||||
Liability for Contingent Milestone Payment, Noncurrent | $ 15,000,000 |
Note 4 - Summary of Significa_4
Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Indefinite intangible asset | $ 77,090 | $ 77,090 |
Istaroxime Drug Candidate [Member] | ||
Indefinite intangible asset | 22,340 | |
Rostafuroxin Drug Candidate [Member] | ||
Indefinite intangible asset | $ 54,750 |
Note 5 - License Revenue with_3
Note 5 - License Revenue with Affiliate - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
License [Member] | ||
License revenue with affiliate | $ 40 | $ 204 |
Note 6 - Fair Value of Financ_3
Note 6 - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Cash and cash equivalents | $ 2,053 | $ 5,234 |
Total Assets | 15,738 | 25,317 |
Certificates of Deposit [Member] | ||
Certificate of deposit | 171 | 171 |
US Treasury Securities [Member] | ||
Cash and cash equivalents | 19,912 | |
Cash and cash equivalents | 13,514 | |
Fair Value, Inputs, Level 1 [Member] | ||
Cash and cash equivalents | 2,053 | 5,234 |
Total Assets | 15,738 | 25,317 |
Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member] | ||
Certificate of deposit | 171 | 171 |
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member] | ||
Cash and cash equivalents | 19,912 | |
Cash and cash equivalents | 13,514 | |
Fair Value, Inputs, Level 2 [Member] | ||
Cash and cash equivalents | ||
Total Assets | ||
Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member] | ||
Certificate of deposit | ||
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member] | ||
Cash and cash equivalents | ||
Cash and cash equivalents | ||
Fair Value, Inputs, Level 3 [Member] | ||
Cash and cash equivalents | ||
Total Assets | ||
Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member] | ||
Certificate of deposit | ||
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member] | ||
Cash and cash equivalents | ||
Cash and cash equivalents |
Note 7 - Loan Payable (Details
Note 7 - Loan Payable (Details Textual) $ in Millions | Dec. 21, 2018USD ($) | Apr. 30, 2019USD ($) | Mar. 31, 2018USD ($) | Jan. 31, 2018USD ($) | Mar. 31, 2019USD ($) | Mar. 31, 2018USD ($) | Dec. 31, 2018USD ($) | Nov. 16, 2018USD ($) | Sep. 30, 2016USD ($) | Sep. 30, 2016TWD ($) |
Repayments of Short-term Debt, Total | $ 447,000 | |||||||||
Short-term Debt, Total | 7,469,000 | $ 7,974,000 | ||||||||
Debt Payable to Lee's International [Member] | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.00% | |||||||||
Debt Instrument, Face Amount | $ 3,500,000 | |||||||||
Repayments of Short-term Debt, Total | 450,000 | |||||||||
Short-term Debt, Total | 3,000,000 | |||||||||
Debt Payable to Lee's International [Member] | Subsequent Event [Member] | ||||||||||
Repayments of Short-term Debt, Total | $ 50,000 | |||||||||
Debt Payable to Lee's International [Member] | Debt Maturing April 2019 [Member] | ||||||||||
Debt Instrument, Face Amount | 500,000 | |||||||||
Debt Payable to Lee's International [Member] | Debt Maturing September 2019 [Member] | ||||||||||
Debt Instrument, Face Amount | 300,000 | |||||||||
Debt Payable to Lee's International [Member] | Debt Maturing October 2019 [Member] | ||||||||||
Debt Instrument, Face Amount | 200,000 | |||||||||
Debt Payable to Lee's International [Member] | Debt Maturing November 2019 [Member] | ||||||||||
Debt Instrument, Face Amount | $ 2,500,000 | |||||||||
Debt Payable to Lee's International [Member] | CVie Investments [Member] | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt | $ 3,500,000 | |||||||||
Loan Payable Obligation Converted to LPH II [Member] | ||||||||||
Debt Conversion, Original Debt, Amount | 6,000,000 | |||||||||
LPH [Member] | ||||||||||
Proceeds from Issuance of Debt | $ 1,000,000 | $ 1,500,000 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.00% | |||||||||
LPH [Member] | Loan Payable Obligation Converted to LPH II [Member] | Debt Issued on January 2018 [Member] | ||||||||||
Debt Conversion, Original Debt, Amount | 1,500,000 | |||||||||
LPH [Member] | Loan Payable Obligation Converted to LPH II [Member] | Debt Issued on March 2018 [Member] | ||||||||||
Debt Conversion, Original Debt, Amount | $ 1,000,000 | |||||||||
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member] | ||||||||||
Line of Credit Facility, Percent of Pledged Deposits Required | 110.00% | |||||||||
Line of Credit, Current | $ 4,500,000 | $ 4,500,000 | ||||||||
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member] | Taipei Interbank Offer Rate (TAIBOR) [Member] | ||||||||||
Debt Instrument, Basis Spread on Variable Rate | 0.91% | |||||||||
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member] | CVie Investments [Member] | ||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 2,900,000 | $ 5.8 | ||||||||
O-Bank Co., Ltd. [Member] | CVie Investments [Member] | Revolving Credit Facility [Member] | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Total | $ 4,500,000 |
Note 8 - Restructured Debt Li_3
Note 8 - Restructured Debt Liability (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | Nov. 01, 2017 | Mar. 31, 2019 | Dec. 31, 2018 |
Liability for Contingent Milestone Payment, Noncurrent | $ 15,000 | $ 15,000 | |
Deerfield Loan [Member] | |||
Liability for Contingent Milestone Payment, Noncurrent | $ 15,000 | $ 15,000 | |
Deerfield Loan [Member] | Exchange and Termination Agreement [Member] | Deerfield Management, L.P. [Member] | |||
Extinguishment of Debt, Amount | $ 25,000 | ||
Class of Warrant or Right, Number of Warrants Cancelled | 25,000 | ||
Class of Warrant or Right, Exercise Price of Cancelled Warrants | $ 786.80 | ||
Repayments of Long-term Debt, Total | $ 2,500 | ||
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations | 71,111 | ||
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations, Percentage of Fully-diluted Shares Outstanding | 2.00% | ||
Liability for Contingent Milestone Payment, Noncurrent | $ 15,000 |
Note 8 - Restructured Debt Li_4
Note 8 - Restructured Debt Liability - Long-term Debt (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Restructured debt liability - contingent milestone payments | $ 15,000 | $ 15,000 |
Deerfield Loan [Member] | ||
Restructured debt liability - contingent milestone payments | $ 15,000 | $ 15,000 |
Note 9 - Stock Options and St_3
Note 9 - Stock Options and Stock-based Employee Compensation (Details Textual) - The 2011 Long-term Incentive Plan [Member] | 3 Months Ended |
Mar. 31, 2019 | |
Stock-based Awards [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period | 3 years |
Restricted Stock Units (RSUs) [Member] | Minimum [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period | 180 days |
Restricted Stock Units (RSUs) [Member] | Maximum [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period | 1 year 180 days |
Note 9 - Stock Options and St_4
Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Stock Option Activity (Details) shares in Thousands | 3 Months Ended |
Mar. 31, 2019$ / sharesshares | |
Shares Outstanding, Beginning Balance (in shares) | shares | 4,417 |
Weighted Average Exercise Price, Outstanding, at Beginning Period (in dollars per share) | $ / shares | $ 6.73 |
Shares Granted (in shares) | shares | 824 |
Weighted Average Exercise Price, Granted (in dollars per share) | $ / shares | $ 4.11 |
Shares Forfeited or Expired (in shares) | shares | (4) |
Weighted Average Exercise Price, Forfeited or Expired (in dollars per share) | $ / shares | $ 576.33 |
Shares Outstanding, Ending Balance (in shares) | shares | 5,237 |
Weighted Average Exercise Price, Outstanding, at Ending Period (in dollars per share) | $ / shares | $ 5.91 |
Weighted Average Remaining Contractual Life, Outstanding (Year) | 9 years 255 days |
Shares Vested and Exercisable (in shares) | shares | 69 |
Weighted Average Exercise Price, Vested and Exercisable (in dollars per share) | $ / shares | $ 130.39 |
Weighted Average Remaining Contractual Life, Vested and Exercisable (Year) | 6 years 255 days |
Vested and expected to vest (in shares) | shares | 4,942 |
Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share) | $ / shares | $ 5.89 |
Weighted Average Remaining Contractual Life, Vested and Expected to Vest (Year) | 9 years 255 days |
Note 9 - Stock Options and St_5
Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands | 3 Months Ended |
Mar. 31, 2019$ / sharesshares | |
Unvested, Beginning Balance (in shares) | shares | 151 |
Unvested, Beginning Balance (in dollars per share) | $ / shares | $ 4.29 |
Awarded (in shares) | shares | 249 |
Awarded (in dollars per share) | $ / shares | $ 3.95 |
Vested (in shares) | shares | (95) |
Vested (in dollars per share) | $ / shares | $ 3.95 |
Cancelled (in shares) | shares | (144) |
Cancelled (in dollars per share) | $ / shares | $ 4.33 |
Unvested, Ending Balance (in shares) | shares | 161 |
Unvested, Ending Balance (in dollars per share) | $ / shares | $ 4.22 |
Note 9 - Stock Options and St_6
Note 9 - Stock Options and Stock-based Employee Compensation - Stock Options Valuation Assumptions (Details) | 3 Months Ended |
Mar. 31, 2019 | |
Weighted average expected volatility | 96.00% |
Weighted average expected term (Year) | 6 years 182 days |
Weighted average risk-free interest rate | 2.60% |
Expected dividends |
Note 9 - Stock Options and St_7
Note 9 - Stock Options and Stock-based Employee Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Stock-based compensation expense | $ 1,530 | $ 418 |
Research and Development Expense [Member] | ||
Stock-based compensation expense | 489 | 110 |
General and Administrative Expense [Member] | ||
Stock-based compensation expense | $ 1,041 | $ 308 |
Note 10 - Leases (Details Textu
Note 10 - Leases (Details Textual) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Lessee, Operating Lease, Liability, Payments, Due, Total | $ 2,241 | $ 2,100 |
Note 10 - Leases - Lease Costs
Note 10 - Leases - Lease Costs (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Operating lease cost | $ 238 |
Variable lease cost | 7 |
Total lease cost | 245 |
Operating cash flows used for operating leases | $ 253 |
Weighted average remaining lease term (in years) (Year) | 2 years 328 days |
Weighted average incremental borrowing rate | 9.00% |
Note 10 - Leases - Future Minim
Note 10 - Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
2019 (excluding the three months ended March 31, 2019) | $ 699 | |
2020 | 666 | |
2021 | 654 | |
2022 | 194 | |
2023 | 28 | |
Thereafter | ||
Total lease payments | 2,241 | $ 2,100 |
Less imputed interest | (260) | |
Total operating lease liabilities at March 31, 2019 | $ 1,981 |